New — News — Vivaldi Biosciences

Posts in New

Vivaldi Biosciences Receives Grant to Study its Universal Flu Vaccine’s Ability to Block Virus Transmission FORT COLLINS, Colorado and VIENNA, Austria – December 18, 2023 – Vivaldi Biosciences today announced it has received a grant fr

NewCarrie WickDecember 17, 2023

EU Grant Supports Universal Influenza Vaccine Clinical Development Leiden, The Netherlands – 5 June 2023 – A consortium of eight academic and industry partners is advancing the development of a universal influenza vaccine with a €7.6 m

NewCarrie WickJune 4, 2023

Vivaldi Biosciences to Present Universal Influenza Vaccine Data at World Vaccine Congress

Vivaldi Biosciences to Present Universal Influenza Vaccine Data at World Vaccine Congress

NewCarrie WickMarch 28, 2023

Vivaldi Biosciences to Present Data on COVID/Influenza Nasal Spray Vaccine at American Society for Virology Annual Meeting FORT COLLINS, Colorado and VIENNA, Austria – July 13, 2022 – Vivaldi Biosciences, a

NewCarrie WickJuly 13, 2022

Vivaldi Biosciences Files PCT Patent Application for Universal Flu and Covid-19 Combination Vaccine FORT COLLINS, Colorado and VIENNA, Austria – November 29, 2021 – Vivaldi Biosciences, a clinical-stage biotechnology company devel

NewCarrie WickNovember 29, 2021

Nasal-Spray Combined Vaccine for Covid and Flu Shows Protection FORT COLLINS, Colorado and VIENNA, Austria – October 6, 2021 – Vivaldi Biosciences, a clinical-stage biotechnology company developing genetically engineered intranasal vac

NewCarrie WickOctober 6, 2021

Vivaldi Biosciences Files Patent Application for Delta-19 Combination Covid-19 + Universal Influenza Vaccine FORT COLLINS, Colorado and VIENNA, Austria – November 23, 2020 – Vivaldi Biosciences, a clinical-stage biotechnology compan

NewCarrie WickNovember 23, 2020

Vivaldi Biosciences Announces Presentation at American Society for Virology Virtual Annual Meeting FORT COLLINS, Colorado and VIENNA, Austria – June 15, 2020 – Vivaldi Biosciences, a clinical-stage biotechnology company developing the

NewCarrie WickJune 14, 2020

Universal Influenza Vaccine Company Vivaldi Biosciences and Blue Sky Vaccines Form Agreement on High Growth Influenza Strain Technology − Vivaldi’s DeltaFLU Addresses Goals of President’s Executive Order on Modernizing Influenza Vacci

NewCarrie WickOctober 13, 2019

Universal Influenza Vaccine Company Vivaldi Biosciences Forms Agreement with BlueSky Vaccines for Virus Purification Technologies FORT COLLINS, Colorado and VIENNA, Austria – July 18, 2019 − Vivaldi Biosciences Inc., a clinical-stage c

NewCarrie WickJuly 18, 2019

DeltaFLU pandemic influenza vaccine shows superior antibody response in clinical trial  − Results Published in the Journal Vaccine − FORT COLLINS, Colorado and VIENNA, Austria – June 19, 2019 -- Vivaldi Biosciences, a clinical-

NewCarrie WickJune 18, 2019

Real-time stability testing of DeltaFLU shows no titer loss after 2 years in storage Influenza pandemic preparedness requires rapid availability of hundreds of millions of doses of an appropriate and effective vaccine. Strategies for p

NewYoy Design AgencyMay 17, 2019

Vivaldi presents data at World Vaccine Congress demonstrating potential of DeltaFLU as universal influenza vaccine – DeltaFLU Outperformed Licensed Vaccine Against Drifted and Shifted Influenza Strains – FORT COLLINS, Colorado – April

NewYoy Design AgencyMay 17, 2019